The Merck Group Website
The Merck Group Website


Ovidrel®/Ovitrelle® (choriogonadotropin alfa) is indicated for the treatment of anovulation, or absence of ovulation, the most common cause of infertility in women. Ovidrel®/Ovitrelle® is administered to trigger ovulation and luteinization in anovulatory or oligo-ovulatory patients after stimulation of follicular growth. It is also administered in women prior to assisted reproductive techniques such as in vitro fertilization (IVF) to trigger final follicular maturation and luteinization after stimulation of follicular growth.

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.